|
|
|
|
Prezista Now Approved as Part of Combination Therapy for Pediatric Patients Six Years of Age and Older with HI
PREZISTA* Now Approved as Part of Combination Therapy for Pediatric Patients Six Years of Age and Older with HIV Approval based on DELPHI study that demonstrated 74 per cent of pediatric patients taking PREZISTA in combination with other...
|
|
|
Prezista (darunavir) labeling changes reflect 96 week study data
(01/29/10) label pdf U.S.Food & Drug Administration (FDA) On January 27, 2010, FDA approved revisions to the Prezista (darunavir) product labeling to include the 96 week data from two trials; one trial in treatment-experienced patients (TMC114-C214...
|
|
|
FDA Announces Label Changes for Darunavir (Prezista), Didanosine (Videx), and Lopinavir/ritonavir (Kaletra)
Below are edited excerpts from the 3 recent FDA announcements.2/2/10 Sources R Klein and K Struble. Prezista (darunavir) labeling changes reflect 96 week study data. HIV/AIDS Update. January 28, 2010 R Klein and K Struble. Videx EC/Videx ...
|
|
|
HIV/AIDS Update - Prezista (darunavir) labeling changes reflect 96 week study data
FDA approved revisions to the Prezista (darunavir) product labeling to include the 96 week data from two trials; one trial in treatment-experienced patients (TMC114-C214) and one trial in treatment-nave patients (TMC114-C211).Section 6: Adverse...
|
|
|
Merck & Co: potential remains for HIV drug despite trial disappointment
New HIV treatment vicriviroc has failed to meet its primary efficacy endpoint in two Phase III clinical trials.As a result, developer Merck & Co has opted to temporarily suspend seeking FDA approval for the drug in treatment-experienced patients. The...
|
|
|
Tibotec gets US FDA nod for labelling update for Prezista tabs
Tibotec Therapeutics announced that the US Food and Drug Administration (FDA) has approved a labelling update for Prezista (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN studies.Both ARTEMIS and TITAN evaluated the efficacy and...
|
|
|
U.S. Food and Drug Administration Approves Labeling Update for Prezista to Include 96-Week Data in HIV-1 Infec
BRIDGEWATER, N.J., Jan.27 /PRNewswire/ -- Tibotec Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a labeling update for PREZISTA (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN studies...
|
|
|
U.S. Food And Drug Administration Approves Labeling Update For PREZISTA(R) To Include 96-Week Data In HIV-1 In
HIV / AIDS News Main Category: HIV / AIDS Also Included In: Regulatory Affairs / Drug Approvals; Clinical Trials / Drug Trials; Pharma Industry / Biotech Industry email to a friend printer friendly view / write opinions Current Article Ratings: Patient / Public...
|
|
|
U.S. Food and Drug Administration Approves Labeling Update for PREZISTA(R) To Include 96-Week Data in HIV-1 Infected Adult Patients
BRIDGEWATER, N.J., Jan.27 /PRNewswire/ -- Tibotec Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a labeling update for PREZISTA (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN studies...
|
|
|
FDA Approves Labeling Update for PREZISTA To Include 96-Week Data in HIV-1 Infected Adult Patients
Tibotec Therapeutics announced today that the FDA has approved a labeling update for PREZISTA (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN studies.Both ARTEMIS and TITAN evaluated the efficacy and safety of PREZISTA with...
|
|
|
Labeling update for Tibotec Therapeutics' PREZISTA tablets approved
Tibotec Therapeutics announced today that the U.S.Food and Drug Administration (FDA) has approved a...Researchers develop new technique for pH adjustmentsHow do individual cells or proteins react to changing pH levels? Researchers at the MESA+ Institute .....
|
|
|
U.S. Food and Drug Administration Approves Labeling Update for PREZISTA(R) To Include 96-Week Data in HIV-1 Infected Adult Patients
BRIDGEWATER, N.J., Jan.27 /PRNewswire/ -- Tibotec Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a labeling update for PREZISTA (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN studies...
|
|
|
U.S. Food and Drug Administration Approves Labeling Update for PREZISTA(R) To Include 96-Week Data in HIV-1 Infected Adult Patients
BRIDGEWATER, N.J., Jan.27 /PRNewswire/ -- Tibotec Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a labeling update for PREZISTA (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN studies...
|
|
|
U.S. Food and Drug Administration Approves Labeling Update for PREZISTA(R) To Include 96-Week Data in HIV-1 Infected Adult Patients (AEGiS)
Food and Drug Administration Approves Labeling Update for PREZISTA(R) To Include 96-Week Data in HIV-1 Infected Adult Patients PRNewswire - January 27, 2010 http://www.aegis.org/news/pr/2010/PR100113.html BRIDGEWATER, N.J., Jan.27 /PRNewswire/ -- Tibotec...
|
|
|
U.S. Food and Drug Administration Approves Labeling Update for PREZISTA(R) To Include 96-Week Data i
BRIDGEWATER, N.J., Jan.27 /PRNewswire/ -- Tibotec Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a labeling update for PREZISTA(R) (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN studies.
|
|
|
Food and Drug Administration Approves Labeling Update for Prezista
Tibotec Therapeutics announced that the U.S.Food and Drug Administration Approves Labeling Update for Prezista.
|
|
|
U.S. Food and Drug Administration Approves Labeling Update for PREZISTA(R) To Include 96-Week Data in HIV-1 Infected Adult Patients
Tibotec Therapeutics announced today that the U.S.Food and Drug Administration (FDA) has approved a labeling update for PREZISTA(R) (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN studies. Both ARTEMIS and TITAN evaluated the...
|
|
|
FDA approves labeling update for HIV drug
BRIDGEWATER,N.J.(Jan. 28) Tibotec Therapeutics announced Thursday that the Food and Drug Administration has approved a labeling update for its HIV drug tablets to include 96-week data from the two studies. The two studies, Artemis and Titan, examined the...
|
|
|
J&J Beats, Guidance Disappoints
Johnson & Johnson (JNJ) reported fourth quarter earnings of 79 cents, which was impacted by a restructuring charge.However, excluding extraordinary items, the company's earnings per share came in at $1.02, surpassing the Zacks Consensus Estimate of...
|
|
|
AIDS clinics ban Merck sales reps
The largest HIV/AIDS healthcare provider has banned Merck's sales reps from its clinics, saying that the company has overpriced its drug Isentress.AIDS Healthcare Foundation has been protesting the cost of Isentress for some time with no luck, but it hopes that...
|
|
|
J&J Q4: Beats Estimates, Guidance Disappoints
Johnson & Johnson (JNJ) reported fourth quarter earnings of 79 cents, which was impacted by a restructuring charge.However, excluding extraordinary items, the companys earnings per share came in at $1.02, surpassing the Zacks Consensus Estimate of 97...
|
|
|
Merck & Co: potential remains for HIV drug despite trial disappointment
(Datamonitor via COMTEX) New HIV treatment vicriviroc has failed to meet its primary efficacy endpoint in two Phase III clinical trials.As a result, developer Merck & Co has opted to temporarily suspend seeking FDA approval for the drug in treatment...
|
|
|
Controversy around Merck's pricing for its AIDS drug Isentress
The controversy around Merck and Co.Pharmaceuticals pricing for its key AIDS drug Isentress at nearly $13,000 per patient yearly, the most expensive first line AIDS therapy on the US market today continued this week following Mercks reaction to recent public...
|
|
|
Merck Rewrites History on Pricing Top AIDS Drug, Isentress, Says ...
Company: Merck & Co., Inc.(MRK) In its press statement dated January 12, 2010, Merck officials claimed, "When ISENTRESS was approved, we established its price with the expectation that it would become first-line treatment," said Patrick Bergstedt, senior...
|
|
|
MONET Study Finds Boosted Darunavir (Prezista) Monotherapy Maintains HIV Suppression as well as Standard Combi
While has proven highly successful, researchers have explored simplified regimens that potentially could increase convenience and adherence while decreasing side effects and costs.One such strategy is protease inhibitor (PI) monotherapy (the small boosting...
|
